Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603614 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment
A Phase 1 study, sponsored by Capricor.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02603614 is a Phase 1 study that has completed, run by Capricor. The registered enrollment target is 8 participants.
The verdict
NCT02603614, a Phase 1 study, has completed, sponsored by Capricor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
CNDP-578-02 is a randomized, double-blind, placebo-controlled, dose-escalation, crossover design trial. Eight evaluable subjects (n=8) with chronic stable heart failure and moderate renal impairment will be randomized (1:1) to receive cenderitide or placebo. Enrolled subjects will begin with Infusion Period A where they will receive up to 7 days of continuous, subcutaneous, dose-escalating infusions of cenderitide or placebo via the Insulet Drug Delivery System. Enrolled subjects will then cross over into Infusion Period B where they will receive up to 7 days of continuous, subcutaneous, dose-escalating infusions of cenderitide or placebo.
Interventions
- DRUG Placebo
- DRUG Cenderitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603614
The ClinicalTrials.gov registry entry for NCT02603614 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Capricor, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02603614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02603614 about?
NCT02603614 is a clinical study titled "Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment". CNDP-578-02 is a randomized, double-blind, placebo-controlled, dose-escalation, crossover design trial. Eight evaluable subjects (n=8) with chronic stable heart failure and moderate renal impairment will be randomized (1:1) to receive cenderitide or placebo. Enrolled subjects will begin with Infusio...
What is the current status of trial NCT02603614?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-12. Estimated completion is 2016-03-31.
What interventions are being tested in trial NCT02603614?
The interventions under investigation include: Placebo (DRUG), Cenderitide (DRUG).
Who is sponsoring clinical trial NCT02603614?
This trial is sponsored by Capricor, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.